propanolamines

Summary

Summary: AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives.

Top Publications

  1. ncbi Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol
    Raffael Fraga
    Heart Institute InCor, University of Sao Paulo, Medical School, Sao Paulo, Brazil
    Eur J Heart Fail 9:630-6. 2007
  2. ncbi Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
    Philip A Poole-Wilson
    National Heart and Lung Institute, Imperial College, London, UK
    Lancet 362:7-13. 2003
  3. ncbi Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN)
    Michel Komajda
    Institut de Cardiologie, Centre Hospitalier GH Pitié Salpêtrière, 47 83 bld de l Hôpital, 75013, Paris Cedex 13, France
    Eur J Heart Fail 6:467-75. 2004
  4. ncbi Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients
    Luciana D N J De Matos
    Heart Institute InCor, University of Sao Paulo Medical School, Sao Paulo, Brazil
    J Card Fail 10:496-502. 2004
  5. pmc High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor
    Vadim Cherezov
    Department of Molecular Biology, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 318:1258-65. 2007
  6. pmc Structure of a beta1-adrenergic G-protein-coupled receptor
    Tony Warne
    MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, UK
    Nature 454:486-91. 2008
  7. pmc Structure and function of an irreversible agonist-β(2) adrenoceptor complex
    Daniel M Rosenbaum
    Department of Molecular and Cellular Physiology, Stanford University School of Medicine, 279 Campus Drive, Stanford, California 94305, USA
    Nature 469:236-40. 2011
  8. pmc Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor
    Michael P Bokoch
    Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, California 94305, USA
    Nature 463:108-12. 2010
  9. ncbi Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial
    H J Dargie
    Department of Cardiology, Western Infirmary, G11 2NT, Glasgow, UK
    Lancet 357:1385-90. 2001
  10. ncbi Distinctive effects of carvedilol in the non-infarct zone: remodelling of the ligated rat heart linked to oxidative stress
    X F Zhuang
    Department of Cardiology, Peking University People s Hospital, Beijing, China
    J Int Med Res 37:1354-64. 2009

Detail Information

Publications283 found, 100 shown here

  1. ncbi Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol
    Raffael Fraga
    Heart Institute InCor, University of Sao Paulo, Medical School, Sao Paulo, Brazil
    Eur J Heart Fail 9:630-6. 2007
    ..Exercise training in HF reduces MSNA and improves forearm vascular resistance and functional capacity...
  2. ncbi Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
    Philip A Poole-Wilson
    National Heart and Lung Institute, Imperial College, London, UK
    Lancet 362:7-13. 2003
    ..We aimed to compare the effects of carvedilol and metoprolol on clinical outcome...
  3. ncbi Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN)
    Michel Komajda
    Institut de Cardiologie, Centre Hospitalier GH Pitié Salpêtrière, 47 83 bld de l Hôpital, 75013, Paris Cedex 13, France
    Eur J Heart Fail 6:467-75. 2004
    ..Management guidelines for heart failure recommend ACE-I and beta-blockers. The perception of difficult up-titration might have added to the slow uptake of beta-blockers despite their mortality and morbidity benefits...
  4. ncbi Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients
    Luciana D N J De Matos
    Heart Institute InCor, University of Sao Paulo Medical School, Sao Paulo, Brazil
    J Card Fail 10:496-502. 2004
    ..The long-term effects of carvedilol on muscle sympathetic nerve activity (MSNA) and muscle blood flow at rest and exercise in patients with chronic heart failure (CHF) remain unknown...
  5. pmc High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor
    Vadim Cherezov
    Department of Molecular Biology, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 318:1258-65. 2007
    ....
  6. pmc Structure of a beta1-adrenergic G-protein-coupled receptor
    Tony Warne
    MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, UK
    Nature 454:486-91. 2008
    ....
  7. pmc Structure and function of an irreversible agonist-β(2) adrenoceptor complex
    Daniel M Rosenbaum
    Department of Molecular and Cellular Physiology, Stanford University School of Medicine, 279 Campus Drive, Stanford, California 94305, USA
    Nature 469:236-40. 2011
    ....
  8. pmc Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor
    Michael P Bokoch
    Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, California 94305, USA
    Nature 463:108-12. 2010
    ..Moreover, these studies provide a new insight into the dynamic behaviour of GPCRs not addressable by static, inactive-state crystal structures...
  9. ncbi Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial
    H J Dargie
    Department of Cardiology, Western Infirmary, G11 2NT, Glasgow, UK
    Lancet 357:1385-90. 2001
    ..We investigated the long-term efficacy of carvedilol on morbidity and mortality in patients with left-ventricular dysfunction after acute myocardial infarction treated according to current evidence-based practice...
  10. ncbi Distinctive effects of carvedilol in the non-infarct zone: remodelling of the ligated rat heart linked to oxidative stress
    X F Zhuang
    Department of Cardiology, Peking University People s Hospital, Beijing, China
    J Int Med Res 37:1354-64. 2009
    ..This study may help provide a mechanistic explanation for the greater benefits shown by carvedilol compared with metoprolol in treating heart failure...
  11. pmc Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors
    Mounia Azzi
    Department of Biochemistry, Universite de Montreal, Montreal, QC, Canada H3C 3J7
    Proc Natl Acad Sci U S A 100:11406-11. 2003
    ..These results point to a multistate model of receptor activation in which ligand-specific conformations are capable of differentially activating distinct signaling partners...
  12. ncbi Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators
    M R Bristow
    Division of Cardiology, University of Colorado HSC, Denver 80262, USA
    Circulation 94:2807-16. 1996
    ..We conducted a multicenter, placebo-controlled trial designed to establish the efficacy and safety of carvedilol, a "third-generation" beta -blocking agent with vasodilator properties, in chronic heart failure...
  13. ncbi Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure
    John R Bullinga
    Division of Cardiology, New York University, New York, NY, USA
    J Card Fail 11:693-9. 2005
    ..Reduced heart rate variability (HRV) has been shown to predict mortality in heart failure (CHF). The relationship between improved cardiac function and improvement in HRV has not been previously studied...
  14. ncbi GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function
    Daniel M Rosenbaum
    Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Science 318:1266-73. 2007
    ..Amino acids known to regulate receptor function are linked through packing interactions and a network of hydrogen bonds, suggesting a conformational pathway from the ligand-binding pocket to regions that interact with G proteins...
  15. ncbi Myocardial autophagy variation during acute myocardial infarction in rats: the effects of carvedilol
    Jing lan Zhang
    Department of Surgical Intensive Care Unit, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
    Chin Med J (Engl) 122:2372-9. 2009
    ..The aim of the present study was to establish a rat model of AMI and observe changes in autophagy in different zones of the myocardium and the effects of carvedilol on autophagy in AMI rats...
  16. ncbi β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFκB and AP-1
    Dong Zhang
    Department of Hepatobiliary and Pancreas Surgery, First Affiliated Hospital, Xi an Jiaotong University, China
    Cancer Biol Ther 10:19-29. 2010
    ..However, β1-adrenergic antagonists suppressed invasion by inhibiting only the cAMP/PKA pathway, suggesting that they may be useful as novel preventive and therapeutic strategies for pancreatic cancer...
  17. ncbi Mutated human beta3-adrenergic receptor (Trp64Arg) lowers the response to beta3-adrenergic agonists in transfected 3T3-L1 preadipocytes
    K Kimura
    Department of Biomedical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan
    Horm Metab Res 32:91-6. 2000
    ....
  18. ncbi Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response
    Matthias Pauschinger
    Department of Internal Medicine II, Cardiology and Pneumonology, Charite University Medicine Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, D 12200 Berlin, Germany
    Eur J Heart Fail 7:444-52. 2005
    ..Beta-adrenergic receptor stimulation influences the production of cytokines heralding the possibility of modulating cytokine production by beta-adrenergic blockers...
  19. ncbi Differential effects of carvedilol and metoprolol on renal function in patients with heart failure
    Hiroyuki Ito
    Cardiology Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
    Circ J 74:1578-83. 2010
    ..The aim of the present study was to verify the effects of beta-blockers on renal function in patients with heart failure (HF)...
  20. pmc beta-Adrenoceptor blockers protect against staurosporine-induced apoptosis in SH-SY5Y neuroblastoma cells
    Maya Mikami
    Department of Anesthesiology, Columbia University P and S, New York, NY 10032, USA
    Eur J Pharmacol 589:14-21. 2008
    ....
  21. ncbi Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch
    Lei Shi
    Center for Molecular Recognition, Departments of Pharmacology and Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    J Biol Chem 277:40989-96. 2002
    ..Differential modulation of the accessibility of Cys(6.47) and an engineered Cys(6.52) in wild type and a constitutively active background provides experimental support for the association of this rotamer switch with receptor activation...
  22. pmc A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling
    James W Wisler
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 104:16657-62. 2007
    ..We hypothesize that such signaling may contribute to the special efficacy of carvedilol in the treatment of heart failure and may serve as a prototype for a new generation of therapeutic beta2AR ligands...
  23. ncbi Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas
    D L Weddle
    Carcinogenesis and Developmental Therapeutics Program, College of Veterinary Medicine, University of Tennessee, 2407 River Drive, Knoxville, TN 37996, USA
    Carcinogenesis 22:473-9. 2001
    ....
  24. ncbi Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein
    C Communal
    Myocardial Biology Unit and Cardiovascular Division, Boston University Medical Center, Boston Veterans Affairs Medical Center and Boston University School of Medicine, Boston, MA, USA
    Circulation 100:2210-2. 1999
    ..beta(2)-ARs may couple to a G(i)-mediated signaling pathway that can oppose the actions of adenylyl cyclase...
  25. ncbi Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes
    George L Bakris
    Rush University Medical Center, Chicago, IL 60612, USA
    Hypertension 46:1309-15. 2005
    ..These differences cannot be explained by effects on blood pressure or alpha1-antagonism but may relate to antioxidant properties of carvedilol...
  26. ncbi Carvedilol reduces the inappropriate increase of ventilation during exercise in heart failure patients
    Piergiuseppe Agostoni
    Centro Cardiologico, Monzino, Istituto di Ricovero e Cura a Carattere Scientifico, Istituto di Cardiologia, Universita di Milano, Via Parea 4, 20138 Milan, Italy
    Chest 122:2062-7. 2002
    ....
  27. ncbi 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone from cigarette smoke stimulates colon cancer growth via beta-adrenoceptors
    William K K Wu
    Department of Pharmacology, Faculty of Medicine, The University of Hong Kong, Hong Kong, China
    Cancer Res 65:5272-7. 2005
    ..These findings partly elucidate the carcinogenic actions of cigarette smoke and shed new light on the novel modulatory role of beta-adrenoceptors in the development of colon cancer...
  28. ncbi A critical review of the use of carvedilol in ischemic heart disease
    Carol Chen-Scarabelli
    Center for Heart and Vessel Preclinical Studies, St John Hospital and Medical Center, Wayne State University School of Medicine, Detroit, MI 48236, USA
    Am J Cardiovasc Drugs 12:391-401. 2012
    ..This article reviews the role of carvedilol compared with other β-blockers in the treatment of CHF and post-AMI management...
  29. ncbi Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial
    Andrew Jabbour
    Cardiology Department, St Vincent s Hospital, Liverpool Street, Sydney, New South Wales 2010, Australia
    J Am Coll Cardiol 55:1780-7. 2010
    ....
  30. ncbi Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes
    Shunsuke Goto
    Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Japan
    Am J Nephrol 34:281-90. 2011
    ..Our study investigated the effect of carvedilol (β-blocker), possessing an antioxidant effect, on diabetic bone disease...
  31. ncbi Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carvedilol
    Shu Kasama
    Department of Cardiovascular Medicine, Gunma University School of Medicine, 3 39 15, Showa machi, Maebashi, Gunma 371 0034, Japan
    Eur Heart J 28:989-95. 2007
    ..However, the influence of carvedilol on cardiac (123)I-meta-iodobenzylguanidine (MIBG) scintigraphic findings and left ventricular (LV) remodelling has not been determined in DCM patients...
  32. ncbi Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol
    T L Yue
    Department of Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Circ Res 82:166-74. 1998
    ..The former two actions represent novel and important mechanisms that may contribute to the cardioprotective effects of carvedilol...
  33. ncbi Carvedilol modifies antioxidant status of patients with stable angina
    Jan Kowalski
    Department of Internal Medicine and Cardiological Rehabilitation, Medical University of Łódź, Łódź, Poland
    Cell Mol Biol Lett 13:230-9. 2008
    ..In conclusion, carvedilol enhances antioxidant defense mechanisms in patients with chronic stable angina pectoris...
  34. ncbi The role of Beta-blockers as first-line therapy in hypertension
    Alberto Ranieri De Caterina
    Institute of Cardiology, Catholic University of the Sacred Heart, Policlinico A Gemelli, Largo A Gemelli, 8, 00168, Rome, Italy
    Curr Atheroscler Rep 13:147-53. 2011
    ..It remains to be determined whether newer BBs, such as nebivolol and carvedilol, will be more effective than older compounds in improving cardiovascular prognosis...
  35. ncbi Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy
    Huang Xiaozhen
    The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Shandong University Qilu Hospital, Jinan, Shandong, PR China
    Blood Press 19:40-7. 2010
    ..Whether carvedilol can improve CFR of patients with hypertensive LVH is unknown. We aimed to investigate the effects of carvedilol on CFR in patients with hypertensive LVH...
  36. pmc Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study
    Britt Kveiborg
    Department of Medicine, Naestved Hospital, Naestved, Denmark
    Cardiovasc Diabetol 9:21. 2010
    ..The aim of this study was to examine the effect of metoprolol versus carvedilol on endothelial function and insulin-stimulated endothelial function in patients with type 2 diabetes...
  37. ncbi Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant?
    Piergiuseppe Agostoni
    Centro Cardiologico Monzino, IRCCS, Istituto di Cardiologia, Universita di Milano, Milan, Italy
    Eur J Heart Fail 9:827-33. 2007
    ..The respiratory system is characterized by beta2-receptor prevalence. Airway beta receptors regulate bronchial tone and alveolar beta receptors regulate alveolar fluid re-absorption which influences gas diffusion...
  38. ncbi Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure
    Donatella Del Sindaco
    Cardiology Unit, IRCCS INRCA, Via Cassia 1167, 00198 Rome, Italy
    J Cardiovasc Med (Hagerstown) 8:675-82. 2007
    ..The aim of this study was to compare the safety, tolerability and efficacy of long-term administration of carvedilol in a group of elderly patients with chronic heart failure, with and without concomitant diabetes...
  39. ncbi Carvedilol treatment ameliorates acute coxsackievirus B3-induced myocarditis associated with oxidative stress reduction
    Yue Chun Li
    Department of Cardiology, Second Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China
    Eur J Pharmacol 640:112-6. 2010
    ..These results show that carvedilol but not metoprolol exerts some of its beneficial effects by inhibiting peroxidants...
  40. pmc Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation
    Il Man Kim
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 105:14555-60. 2008
    ..Our findings demonstrate that Alp and Car are ligands that not only act as classical receptor antagonists, but can also stimulate signaling pathways in a G protein-independent, beta-arrestin-dependent fashion...
  41. ncbi Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction
    Bin Li
    Laboratory of Cardiovascular Immunology, Institute of Cardiology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, China
    Int J Cardiol 111:247-55. 2006
    ..The goal of this study was to evaluate the effects of carvedilol on cardiac cytokines expression as well as on myocardial and extracellular matrix remodeling in rats with acute myocardial infarction...
  42. ncbi Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure
    B D Lowes
    Division of Cardiology, University of Colorado Health Sciences Center, Denver 80262, USA
    Am J Cardiol 83:1201-5. 1999
    ..These changes occur in association with an improvement in LV systolic function. This process begins by 4 months of treatment and continues for 12 months...
  43. ncbi Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor
    XiaoJie Yao
    Department of Molecular and Cellular Physiology, Stanford University School of Medicine, 279 Campus Drive, Stanford, Palo Alto, California 94305, USA
    Nat Chem Biol 2:417-22. 2006
    ..Our results show that disruption of this important molecular switch is necessary, but not sufficient, for full activation of the beta2-AR...
  44. pmc The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors
    Jillian G Baker
    Institute of Cell Signalling, C Floor Medical School, Queen s Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK
    Br J Pharmacol 144:317-22. 2005
    ..There is therefore considerable potential for developing more selective beta-antagonists for clinical use and thereby reducing the side-effect profile of beta-blockers...
  45. ncbi The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial
    Michael Domanski
    Clinical Trials Group, National Heart, Lung, and Blood Institute NIH, 6701 Rockledge Drive, Bethesda, MD 20892, USA
    J Am Coll Cardiol 42:914-22. 2003
    ..This was a retrospective analysis to determine the effect of diabetes on outcome in patients with advanced heart failure (HF), and to determine the effect of beta-blockade in patients with HF with and without diabetes mellitus...
  46. ncbi Effect of carvedilol on survival in severe chronic heart failure
    M Packer
    Division of Circulatory Physiology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    N Engl J Med 344:1651-8. 2001
    ..Beta-blocking agents reduce the risk of hospitalization and death in patients with mild-to-moderate heart failure, but little is known about their effects in severe heart failure...
  47. ncbi Intracellular mechanisms of specific beta-adrenoceptor antagonists involved in improved cardiac function and survival in a genetic model of heart failure
    Jan B Bartholomeu
    School of Physical Education and Sport, University of Sao Paulo, Sao Paulo, Brazil
    J Mol Cell Cardiol 45:240-9. 2008
    ....
  48. ncbi Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis
    Rafael Bañares
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital General Universitario Gregorio Maranon, Universidad Complutense, Madrid, Spain
    Hepatology 36:1367-73. 2002
    ..However, its clinical applicability may be limited by its systemic hypotensive effects. Further trials are needed to confirm the therapeutic potential of carvedilol...
  49. ncbi Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy
    J Rhodes
    Department of Cardiology, Children s Hospital Boston, 300 Longwood Avenue, Boston, MA 02115, USA
    Pediatr Cardiol 29:343-51. 2008
    ..This study aimed to evaluate the safety and efficacy of carvedilol for patients with DCM...
  50. ncbi Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats
    Wawaimuli Arozal
    Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265 1 Higashijima Akiha ku, Niigata City 956 8603, Japan
    Toxicology 274:18-26. 2010
    ..In conclusion, the present study demonstrated a beneficial effect of carvedilol treatment in the prevention of DNR-induced cardiotoxicity and nephrotoxicity by reversing the oxidative stress and apoptosis...
  51. ncbi The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients
    Gisli Jonsson
    Department of Cardiology, Ullevaal Hospital, University of Oslo, Oslo, Norway
    J Cardiovasc Pharmacol 49:27-32. 2007
    ..454). These results indicate that carvedilol has a more pronounced antioxidative effect than atenolol in post-AMI patients, which might be of clinical importance...
  52. ncbi Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure
    A Mortara
    Department of Cardiology, Centro Medico di Montescano, S Maugeri Foundation, IRCCS, Pavia, Italy
    J Am Coll Cardiol 36:1612-8. 2000
    ..The purpose of this study was to investigate in a case-controlled study whether carvedilol increased baroreflex sensitivity and heart rate variability (HRV)...
  53. ncbi Carvedilol inhibits tumor necrosis factor-alpha-induced endothelial transcription factor activation, adhesion molecule expression, and adhesiveness to human mononuclear cells
    Jaw Wen Chen
    National Yang Ming University School of Medicine, Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, 201, Sec 2, Shih Pai Road, Taipei, Taiwan 112, Republic of China
    Arterioscler Thromb Vasc Biol 24:2075-81. 2004
    ....
  54. ncbi Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property
    Zuyi Yuan
    Dept of Cardiovascular Medicine, Graduate School of Medicine, Kyoto Univ, 54 Kawaracho, Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Am J Physiol Heart Circ Physiol 286:H83-90. 2004
    ....
  55. ncbi Modulation of amyloid precursor protein processing by synthetic ceramide analogues
    Hongyun Li
    Prince of Wales Medical Research Institute, Randwick, NSW 2031, Australia
    Biochim Biophys Acta 1801:887-95. 2010
    ..In conclusion, this study provides novel information regarding the regulation of APP processing by synthetic ceramide analogues and reveals that the most potent of these compounds is EtDO-P4...
  56. ncbi Association of physical training with beta-blockers in heart failure in mice
    Andréa Somolanji Vanzelli
    Universidade de Sao Paulo, Brazil
    Arq Bras Cardiol 95:373-80. 2010
    ..Currently there are several types of interventions for the treatment of heart failure (HF). Among these are beta-blocker therapy (BB) and physical training (PT). However, the effects of the combination of these therapies are poorly studied...
  57. ncbi Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis
    Tao Cheng Wu
    Institute of Clinical Medicine, School of Medicine, National Yang Ming University, Taipei, Taiwan, Republic of China
    Free Radic Biol Med 43:1508-22. 2007
    ..Accordingly, carvedilol, a pharmacological antioxidant, inhibited in vivo and in vitro expression of MMP-2 and MMP-9 properly by modulating the redox-related pathways, suggesting its potential clinical implications...
  58. ncbi Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials
    Ravinder K Wali
    University of Maryland School of Medicine, Baltimore, MD, USA
    Circ Heart Fail 4:18-26. 2011
    ..We assessed whether treatment of systolic HF with carvedilol is efficacious and safe in adults with CKD...
  59. ncbi Protective antioxidant effects of carvedilol in a rat model of ischaemia-reperfusion injury
    H Akbas
    Department of Cardiovascular Surgery, Kocaeli University School of Medicine, Kocaeli, Turkey
    J Int Med Res 33:528-36. 2005
    ..In conclusion, it might be inferred that carvedilol could be used safely to prevent oxidative injury during reperfusion following ischaemia in humans...
  60. ncbi Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET
    Willem J Remme
    Sticares Cardiovascular Research Institute, Rhoon, The Netherlands
    J Am Coll Cardiol 49:963-71. 2007
    ..We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study...
  61. ncbi Structure and conformational changes in the C-terminal domain of the beta2-adrenoceptor: insights from fluorescence resonance energy transfer studies
    Sebastien Granier
    Department of Molecular, Stanford University School of Medicine, Stanford, California 94305, USA
    J Biol Chem 282:13895-905. 2007
    ..Taken together the results provide new insight into the structure of the C terminus of the beta(2)-AR as well as ligand-induced conformational changes that may be relevant to arrestin-dependent regulation and signaling...
  62. ncbi Does carvedilol impair insulin sensitivity in heart failure patients without diabetes?
    Stefania Ferrua
    University Department of Cardiology, San Giovanni Battista Hospital, Turin, Italy
    J Card Fail 11:590-4. 2005
    ..In this study, the metabolic effect of carvedilol in nondiabetic patients with chronic heart failure (CHF) was evaluated...
  63. ncbi Neuroprotective effect of carvedilol, an adrenergic antagonist against colchicine induced cognitive impairment and oxidative damage in rat
    Anil Kumar
    Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India
    Pharmacol Biochem Behav 92:25-31. 2009
    ..Present study demonstrates a neuroprotective effect of carvedilol against colchicine-induced cognitive impairment and associated oxidative damage...
  64. ncbi A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy
    Fernando A Botoni
    Postgraduate Course of Tropical Medicine, University Hospital, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
    Am Heart J 153:544.e1-8. 2007
    ..The objective of this study was to determine the safety and efficacy of renin-angiotensin system (RAS) inhibitors and beta-blockers in chronic Chagas cardiomyopathy...
  65. ncbi Prospective single-arm protocol of carvedilol in children with ventricular dysfunction
    E D Blume
    Department of Cardiology, Children s Hospital, Boston, 300 Longwood Avenue, Boston, MA 02115, USA
    Pediatr Cardiol 27:336-42. 2006
    ..We conclude that in this prospective protocol of pediatric patients, the use of adjunct carvedilol in the DCM group improved ejection fraction compared to untreated controls and trended toward delaying time to transplant or death...
  66. ncbi Treatment of dilated cardiomyopathy with carvedilol in children
    Ilkay Erdogan
    Pediatric Cardiology Unit, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey
    Turk J Pediatr 51:354-60. 2009
    ..Patient selection criteria, optimal timing of carvedilol therapy, its dosage and its long-term effects need to be investigated with multi-institutional trials and large numbers of patients...
  67. ncbi Coadministration of carvedilol attenuates nitrate tolerance by preventing cytochrome p450 depletion
    Atsushi Nakahira
    Department of Cardiovascular Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
    Circ J 74:1711-7. 2010
    ..The present study investigated how carvedilol attenuates nitrate tolerance, particularly with reference to cytochrome P450 (CYP), an enzyme involved in the development of tolerance...
  68. ncbi [Effect of carvedilol on lipid peroxidation in patients with stable angina]
    Jan Kowalski
    Katedra Rehabilitacji z Klinika Chorób Wewnetrznych i Rehabilitacji Kardiologicznej UM w Łodzi
    Pol Merkur Lekarski 18:156-9. 2005
    ..MDA concentration did not differ in patients from that observed in healthy subjects after 8 and 12 weeks of therapy The results of our study have shown that carvedilol inhibits lipid peroxidation in patients with stable angina...
  69. ncbi Carvedilol: a third-generation β-blocker should be a first-choice β-blocker
    James J Dinicolantonio
    Wegmans Pharmacy, 500 South Meadow Street, Ithaca, NY 14850, USA
    Expert Rev Cardiovasc Ther 10:13-25. 2012
    ..We will provide compelling evidence of why carvedilol should be a first-line β-blocker and why it offers many advantages over the β1-selective β-blockers...
  70. ncbi Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus
    Savina Nodari
    Cattedra di Cardiologia, Universita di Brescia, Piazza Spedali Civili, 25100 Brescia, Italy
    Eur J Heart Fail 5:803-9. 2003
    ..Diabetes is frequently associated with heart failure and is an independent risk factor for an increased mortality and morbidity. Beta-blockers are traditionally regarded as relatively contraindicated in patients with diabetes mellitus...
  71. pmc {Beta}-blocker drugs mediate calcium signaling in native central nervous system neurons by {beta}-arrestin-biased agonism
    Anastassios V Tzingounis
    Department of Physiology and Neurobiology, University of Connecticut, Storrs, CT 06269, USA
    Proc Natl Acad Sci U S A 107:21028-33. 2010
    ..Our results support the emerging view of β-arrestin-biased agonism as a significant mechanism of drug action and do so in CNS-derived neurons expressing only native receptors...
  72. ncbi Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats
    Yong Hyun Kim
    Division of Cardiology, Department of Medicine, Korea University Ansan Hospital, Ansan, Republic of Korea
    Toxicol Mech Methods 22:488-98. 2012
    ..Doxorubicin is widely used anti-neoplastic drug but has serious cardiotoxicity. Long-term cardioprotective effects of statin and carvedilol against delayed cardiotoxicity of doxorubicin was not well elucidated...
  73. pmc Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis
    Li Yue-Chun
    Department of Cardiology, Second Affiliated Hospital of Wenzhou Medical College, Wenzhou, China
    PLoS ONE 7:e39394. 2012
    ..However, the effects of ivabradine in the setting of acute viral myocarditis and on the cytokines, oxidative stress and cardiomyocyte apoptosis have not been investigated...
  74. pmc Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor
    Jillian G Baker
    Institute of Cell Signalling, University of Nottingham, Queen s Medical Centre, Nottingham NG7 2UH
    Br J Pharmacol 137:400-8. 2002
    ....
  75. ncbi Early recovery of impaired coronary flow reserve by carvedilol therapy in patients with idiopathic dilated cardiomyopathy: a serial transthoracic Doppler echocardiographic study
    Kenichi Sugioka
    J Am Coll Cardiol 45:318-9. 2005
  76. ncbi Additive effects of β-blockers on renin-angiotensin system inhibitors for patients after acute myocardial infarction treated with primary coronary revascularization
    Masanori Konishi
    Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Japan
    Circ J 75:1982-91. 2011
    ..Although some β-blockers are effective for patients after acute myocardial infarction (AMI), few studies have compared their additive effects on renin-angiotensin system inhibitors (RAS-Is)...
  77. ncbi Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial
    Marco Metra
    Cattedra di Cardiologia, Universita di Brescia, Italy
    Eur Heart J 26:2259-68. 2005
    ....
  78. ncbi Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients
    D S H Bell
    The University of Alabama, Birmingham, AL, USA
    Diabetes Obes Metab 11:234-8. 2009
    ....
  79. pmc Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses
    Jillian G Baker
    Institute of Cell Signalling, University of Nottingham, Queen s Medical Centre, Nottingham, NG7 2UH, UK
    FASEB J 25:4486-97. 2011
    ..Bucindolol, however, significantly antagonized the response to the highest doses isoprenaline. An excellent correlation was obtained between in vivo and in vitro measures of β1-adrenoceptor efficacy (R(2)=0.93; P<0.0001)...
  80. ncbi Clinical updates on carvedilol: a first choice beta-blocker in the treatment of cardiovascular diseases
    Subhashis Chakraborty
    Banaras Hindu University, Institute of Technology, Department of Pharmaceutics, Varanasi 221005, India
    Expert Opin Drug Metab Toxicol 6:237-50. 2010
    ..Carvedilol, a non-selective beta-blocker, has recently drawn attention because of its therapeutic benefits over other prescribed analogues for the treatment of cardiovascular diseases (CVDs)...
  81. ncbi Body weight changes with beta-blocker use: results from GEMINI
    Franz H Messerli
    St Luke s Roosevelt Hospital Center, New York City, NY 10019, USA
    Am J Med 120:610-5. 2007
    ....
  82. ncbi Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients
    M Moser
    Yale University School of Medicine, New Haven, Connecticut, USA
    Am J Hypertens 11:15S-22S. 1998
    ..The antioxidant and antiproliferative activities of carvedilol may present an advantage over other available antihypertensive medications...
  83. ncbi Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI
    V Fonseca
    Tulane University, New Orleans, LA 70112, USA
    Diabet Med 24:759-63. 2007
    ..To determine whether the beneficial effects of carvedilol on insulin resistance (IR) are affected by the concomitant use of insulin sensitizers [thiazolidinediones (TZDs) and metformin]...
  84. ncbi Effect of esmolol on fluid therapy in normovolemia and hypovolemia
    Michael P Kinsky
    Resuscitation Research Laboratory, Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas 77555 0801, USA
    Shock 30:55-63. 2008
    ..Esmolol reduced DeltaPV/DeltaEVV. These data suggest that esmolol impairs the vascular retention of fluid and may increase the amount of volume support during fluid resuscitation...
  85. ncbi Realities of newer beta-blockers for the management of hypertension
    Camila Manrique
    Department of Internal Medicine, University of Missouri Columbia, Columbia, MO, USA
    J Clin Hypertens (Greenwich) 11:369-75. 2009
    ..Newer beta-blockers may overcome concerns about efficacy, adverse effects, and tolerability, while delivering cardiovascular protection...
  86. ncbi Impact of carvedilol on the serum lipid profile
    Randall P Sharp
    College of Pharmacy, Southwestern Oklahoma State University, Weatherford, OK 73096, USA
    Ann Pharmacother 42:564-71. 2008
    ..To examine the evidence regarding the impact of carvedilol on the serum lipid profile...
  87. pmc The pharmacological effects of the thermostabilising (m23) mutations and intra and extracellular (β36) deletions essential for crystallisation of the turkey β-adrenoceptor
    Jillian G Baker
    Institute of Cell Signalling, C Floor Medical School, University of Nottingham, Queen s Medical Centre, UK
    Naunyn Schmiedebergs Arch Pharmacol 384:71-91. 2011
    ....
  88. ncbi Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review
    Angelo M Carella
    Department of Internal Medicine, T Masselli Mascia Hospital, San Severo, Foggia, Italy
    Curr Diabetes Rev 6:215-21. 2010
    ....
  89. ncbi Carvedilol therapy in pediatric patients with dilated cardiomyopathy
    Hülya Askari
    Section of Cardiology, Department of Pediatrics, Uludag University Faculty of Medicine, Bursa, Turkey
    Turk J Pediatr 51:22-7. 2009
    ..Carvedilol in addition to standard therapy for dilated cardiomyopathy in children improves cardiac function and symptoms. It is well tolerated, with minimal adverse effects, but close monitoring is necessary...
  90. pmc Endothelial function is unaffected by changing between carvedilol and metoprolol in patients with heart failure--a randomized study
    Britt Falskov
    Department of Cardiology, Gentofte Hospital, Hellerup, Denmark
    Cardiovasc Diabetol 10:91. 2011
    ....
  91. ncbi Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice
    Elias N Glaros
    Prince of Wales Medical Research Institute, Randwick, NSW, Australia
    J Lipid Res 49:1677-81. 2008
    ....
  92. ncbi Effects of carvedilol therapy on arrhythmia markers in patients with congestive heart failure
    Bahri Akdeniz
    Department of Cardiology, Dokuz Eylul University School of Medicine, Inciralti, Izmir, Turkey
    Int Heart J 47:565-73. 2006
    ..This prospective controlled study shows that carvedilol therapy decreased QT dispersion and improved ventricular repolarization characteristics but did not change autonomic dysfunction in patients with heart failure...
  93. ncbi The mechanism of carvedilol in experimental viral myocarditis
    Li Yue-Chun
    Department of Cardiology, Second Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China
    Curr Pharm Des 18:1620-4. 2012
    ....
  94. ncbi Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial
    Okan Erdogan
    Department of Cardiology, Faculty of Medicine, Marmara University, Istanbul, Turkey
    Anadolu Kardiyol Derg 11:310-3. 2011
    ..The aim of the present study is to compare the antihypertensive effects of carvedilol and nebivolol in mild-to-moderate hypertensive patients...
  95. ncbi Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo
    Michael Kindermann
    Klinik fur Innere Medizin III, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    Circulation 109:3182-90. 2004
    ..Here, we determined the significance of this phenomenon on human beta-ARs in vitro and in vivo...
  96. pmc Two-year clinical outcome after carvedilol-loaded stent implantation in patients with coronary artery disease
    Hyun Kuk Kim
    Department of Internal Medicine, The Heart Center of Chonnam National University Hospital, Gwangju, Korea
    Korean J Intern Med 26:41-6. 2011
    ..The aim of this study was to investigate the beneficial effects of carvedilol-loaded stents on 2-year clinical outcomes after stent implantation in patients with coronary artery disease...
  97. ncbi Relation of early improvement in coronary flow reserve to late recovery of left ventricular function after beta-blocker therapy in patients with idiopathic dilated cardiomyopathy
    Kenichi Sugioka
    Department of Internal Medicine and Cardiology, Osaka City University Graduate School of Medicine, Osaka, Japan
    Am Heart J 153:1080.e1-6. 2007
    ....
  98. ncbi Differential effects of carvedilol and metoprolol on isoprenaline-induced changes in beta-adrenoceptor density and systolic function in rat cardiac myocytes
    M Flesch
    Klinik III für Innere Medizin der Universität zu Köln, Joseph Stelzmann Strasse 9, 50924, Cologne, Germany
    Cardiovasc Res 49:371-80. 2001
    ..Differences between agents might be important for the development of more specific therapeutical approaches. This study investigated whether metoprolol or carvedilol alter beta-adrenergic signaling differently...
  99. ncbi Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers
    Jorge Polonia
    Faculdade de Medicina do Porto, Hospital Pedro Hispano, Matosinhos, Porto, Portugal
    Blood Press Monit 15:235-9. 2010
    ....
  100. ncbi Carvedilol inhibits right ventricular hypertrophy induced by chronic hypobaric hypoxia
    L Tual
    Universite Paris 13, Laboratoire, Résponses cellulaires et fonctionnelles à l hypoxie, EA 2363, Association pour la Recherche en Physiologie de l Environment, 74 rue Marcen Cachin, 93017, Bobigny, France
    Pflugers Arch 452:371-9. 2006
    ..Carvedilol is effective in reducing hypoxia-induced right ventricular hypertrophy, pulmonary arterial hypertension, and muscularization of pulmonary arteries...
  101. ncbi [Study of carvedilol on plaque stability in carotid atherosclerotic rabbits transfected by p53 gene]
    Yun yuan Guan
    Department of Cardiology, Second Affiliated Hospital of Nantong University, Nantong 226001, China
    Zhonghua Xin Xue Guan Bing Za Zhi 35:63-8. 2007
    ..To investigate the effects of carvedilol on stabilizing atherosclerosis plaque...

Research Grants58

  1. ACTION - A CHF Trial Investigating Outcomes of Exercise
    Gregg Fonarow; Fiscal Year: 2006
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  2. Inflammation in obesity: Modulation by Weight Loss
    Paresh Dandona; Fiscal Year: 2009
    ..abstract_text> ..
  3. AASK Cohort Study
    George Bakris; Fiscal Year: 2007
    ..Such results might eventually lead to new strategies that delay or prevent ESRD. ..
  4. NITROXIDERGIC CEREBROVASCULAR TONE DURING ANESTHESIA
    Shailendra Joshi; Fiscal Year: 2005
    ..abstract_text> ..
  5. Heart failure, chronic kidney disease, and renin-angiotensin system inhibition
    Ali Ahmed; Fiscal Year: 2009
    ....
  6. SOFTWARE EFFECT ON PROMOTING ADHERENCE TO CHF GUIDELINES
    Lawrence Baruch; Fiscal Year: 2005
    ..If this decision support system is successful and widely implemented, the best outcomes from care for chronic heart failure may be achieved. ..
  7. CEREBRAL PROTECTION & RECOVERY AFTER CIRCULATORY ARREST
    Yan Xu; Fiscal Year: 2007
    ..It is hoped that these specific investigations wilt pave the way to ultimately identifying the causal interaction between angiogenesis and neurogenesis after resuscitation from global ischemia. ..
  8. DOPAMINE TRANSPORTER: SUBSTRATE & COCAINE BINDING SITES
    JONATHAN JAVITCH; Fiscal Year: 2007
    ..4) To map the intracellular and extracellular accessibility during different functional states of substituted-cysteines through IL1 and IL3 of DAT. ..
  9. AUTOMATED CARDIAC DECISION SUPPORT SYSTEM IMPROVES CARE
    Lawrence Baruch; Fiscal Year: 2005
    ..If this automated clinical information and decision support system is successful and widely implemented, the best outcomes from care for chronic cardiovascular disease may be achieved. ..
  10. Prognostic significance of T wave variability
    Eric Rashba; Fiscal Year: 2006
    ..2) Patients with increased T wave variability derive a greater mortality benefit from prophylactic ICD implantation. ..
  11. Chemoanatomic bases for peripheral vestibular function
    GAY HOLSTEIN; Fiscal Year: 2007
    ..The proposed research is unique, and will have direct bearing on the development of more effective therapeutic interventions, both medicinal and device-oriented, for peripheral vestibular disorders. [unreadable] [unreadable] [unreadable]..
  12. Mechanisms of Oxidant Signaling in Post-MI Remodeling
    Wilson Colucci; Fiscal Year: 2007
    ..These studies will provide new understanding of the mechanisms of oxidant signaling in myocardial remodeling post-MI, and will therefore have direct relevance to a common cause of heart failure in patients. [unreadable] [unreadable]..
  13. LV Function Assessment Core Lab for IMMEDIATE Trial
    James Udelson; Fiscal Year: 2006
    ..These data Will provide robust information with sufficient power to test the concepts in Hypothesis H9 of the parent trial and provide substantial insights into the mechanism of GIK effect. ..
  14. Arrhythmia Assessment Core Lab for IMMEDIATE Trial
    Eric Rashba; Fiscal Year: 2006
    ..End of abstract.) [unreadable] [unreadable]..
  15. ARCHAEAL & BACTERIAL HOMOLOGS OF DOPAMINE TRANSPORTER
    JONATHAN JAVITCH; Fiscal Year: 2002
    ....
  16. Leptin resistance: 1 mechanism underlying age-related obesity
    PHILIP SCARPACE; Fiscal Year: 2008
    ..Such discoveries may lead to new treatments for obesity and the diabetes associated with obesity. ..
  17. Hyperthermia: Uncoupling the agony from Ecstasy
    JON SPRAGUE; Fiscal Year: 2007
    ..thyrotoxic [unreadable] crisis). [unreadable] [unreadable] [unreadable]..
  18. 2004 & 2006 Membrane Transport Proteins Gordon Conference
    JONATHAN JAVITCH; Fiscal Year: 2005
    ..In keeping with the GRC tradition, the interactions that will result, whether from formal or informal discussions, can be expected to be extraordinarily stimulating and productive. ..
  19. TNF-ALPHA REGULATION OF AT1 RECEPTOR & POST-MI FIBROSIS
    Barry Greenberg; Fiscal Year: 2003
    ..This information will provide important insights into the pathogenesis of post-MI fibrosis. ..
  20. Analysis of a Novel Family of Lipid Receptors
    Yan Xu; Fiscal Year: 2004
    ....
  21. Strain induced myopathy in post infarction heart failure
    Joseph Gorman; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  22. NOVEL RADIOTRACERS FOR ANDROGEN RECEPTOR IMAGING
    MARCIAN VAN DORT; Fiscal Year: 2001
    ..abstract_text> ..
  23. Circulatory Dysfunction in Chronic Fatigue Syndrome
    Julian Stewart; Fiscal Year: 2004
    ....
  24. CEREBROVASCULAR NITRIC OXIDERGIC INNERVATION
    Tony Lee; Fiscal Year: 2005
    ..This research is a step toward our long-term goal to define the transmitter mechanisms in cerebral vasodilation and constriction, and their alterations in cerebral vascular diseases. ..
  25. FOREBRAIN AND HINDBRAIN MECHANISMS OF SALT APPETITE
    ROBERT THUNHORST; Fiscal Year: 2005
    ....
  26. MOP Receptor Effects on the Hippocampal CA1 Network
    ADAM MCQUISTON; Fiscal Year: 2008
    ..The results from these studies will provide important information regarding MOP receptor-induced changes in network activity and may possibly lead to the development of treatments for opioid addiction. ..
  27. Detecting Endothelial Dysfunction in Renal Failure
    Julian Stewart; Fiscal Year: 2007
    ..These data will form the basis of future noninvasive prognostic testing and treatment of patients at risk for ECD and can provide a means to follow treatment modalities. [unreadable] [unreadable] [unreadable]..
  28. ACTION - A CHF Trial Investigating Outcomes of Exercise
    Wilson Colucci; Fiscal Year: 2007
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  29. Myocardial Viability and Remodeling in the OAT
    James Udelson; Fiscal Year: 2008
    ..OAT-NUC is the only viability ancillary study of OAT, and thus serves a critical need in assessing potential mechanisms of the findings in OAT. ..
  30. MOLECULAR RECOGNITION OF ANTIPSYCHOTIC DRUGS AND COCAINE
    JONATHAN JAVITCH; Fiscal Year: 2006
    ..abstract_text> ..
  31. Age-related Obesity: Interventions with Gene Delivery
    PHILIP SCARPACE; Fiscal Year: 2006
    ..Such discoveries may lead to new treatments for obesity and the diabetes associated with obesity. ..
  32. Neurohormonal Blockade and Outcomes in Diastolic Heart Failure
    Ali Ahmed; Fiscal Year: 2010
    ..The proposed study will examine the effect of neurohormonal blockade in propensity matched OPTIMIZE-HF participants with diastolic heart failure. ..
  33. MUCOSAL DEFENSE MECHANISMS IN SUBSTANCE ABUSE
    David R Brown; Fiscal Year: 2010
    ....
  34. NMR STUDIES OF MECHANISMS OF GENERAL ANESTHESIA
    Yan Xu; Fiscal Year: 2003
    ..abstract_text> ..
  35. Androgens raise venous and arterial adrenergic tone.
    Douglas S Martin; Fiscal Year: 2010
    ..A better understanding the factors that control arterial and venous tone in hypertension may lead to design antihypertensive drugs with fewer adverse effects ..
  36. Cocaine Withdrawal and Pharmacotherapy Response
    Mehmet Sofuoglu; Fiscal Year: 2010
    ..This proposal, by testing the efficacy of carvedilol and investigating the influence of withdrawal severity on carvedilol's efficacy, may result in development of more effective treatments for cocaine addiction. ..
  37. Functional Recovery of Sensory Input to Olfactory Bulb
    DALE WACHOWIAK; Fiscal Year: 2009
    ..This work could potentially yield insight into treatment strategies for these and other syndromes related to inappropriate neuronal connections. ..
  38. Equipment Support for USD Laboratory Animal Services
    Douglas Martin; Fiscal Year: 2005
    ..The long-term goal is to achieve AAALAC accreditation. It is expected that AAALAC review for accreditation will be requested within 18 months of completion and occupancy of the new LAS. ..
  39. Electrophysiologic effects of late PCI (OAT-EP)
    Stephen Shorofsky; Fiscal Year: 2005
    ....
  40. GABA Medications for Tobacco Addiction
    Mehmet Sofuoglu; Fiscal Year: 2009
    ..The findings of this study will provide valuable information to develop new pharmacotherapies for smoking cessation. ..
  41. Ecstasy's neurotoxicity: role of hyperthermia
    JON SPRAGUE; Fiscal Year: 2004
    ....
  42. Decision Making in End-Stage Heart Failure
    Paul Hauptman; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  43. Heart Failure and Beta-Blocker Use in Older Adults
    Ali Ahmed; Fiscal Year: 2006
    ..abstract_text> ..
  44. Progestrone and the Effects of Nicotine
    Mehmet Sofuoglu; Fiscal Year: 2006
    ..By characterizing the progesterone effects on nicotine dependence, this study may provide a better understanding of the mechanisms which mediate the sex and menstrual cycle phase effects on nicotine dependence. ..
  45. MORPHOLOGIC BASIS FOR CENTRAL VESTIBULAR INHIBITION
    GAY HOLSTEIN; Fiscal Year: 2002
    ....
  46. TM Domain Structures of Ligand-Gated Ion Channels by NMR
    Yan Xu; Fiscal Year: 2007
    ..abstract_text> ..
  47. ACTION - A CHF Trial Investigating Outcomes of Exercise
    CHRISTOPHER O CONNOR; Fiscal Year: 2008
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  48. IMPAIRED LEPTIN RESPONSIVENESS WITH AGE
    PHILIP SCARPACE; Fiscal Year: 2002
    ..The potential for vitamin A supplementation to reverse the age-related increase in serum leptin and restore leptin responsiveness is addressed in this proposal. ..
  49. CEREBRAL VESSEL INNERVATION IN HYPERTENSION
    Tony Lee; Fiscal Year: 2002
    ..This research is a step toward our long-term goal to define the transmitter mechanisms in cerebral vasodilation and constriction, and their alterations in cerebral vascular diseases. ..
  50. Software Promotes NCEP/AHA Provider Guideline Adherence
    Lawrence Baruch; Fiscal Year: 2003
    ..If this automated clinical information and decision support system is successful and widely implemented, the best outcomes from care for chronic cardiovascular disease may be achieved. ..
  51. CONTRACTILE PROTEIN EXPRESSION IN FAILING HUMAN HEART
    Michael Bristow; Fiscal Year: 2002
    ..The data generated in this proposal should determine if altered expression of contractile proteins is a molecular explanation for systolic dysfunction in the failing human heart, and if this system can be targeted therapeutically. ..
  52. Central betal adrenergic receptors and behavior
    Han Ting Zhang; Fiscal Year: 2004
    ..This will lead to the better understanding of pathophysiology and pharmacotherapy of depression. ..
  53. Dopamine Effects On Memory Consolidation
    Ryan LaLumiere; Fiscal Year: 2004
    ..These findings may provide insight into disorders of memory, such as posttraumatic stress disorder, as well as into the connections between emotionally influenced memory consolidation and addiction processes. ..
  54. Dynamic Expression Profiling in the Intact Human Heart
    Michael Bristow; Fiscal Year: 2003
    ....
  55. Genetic-Adrenergic Interactions in Myocardial Failure
    Michael Bristow; Fiscal Year: 2007
    ..abstract_text> ..
  56. Synaptic Transmission, Plasticity and Integration in the Subthalamic Nucleus
    Mark D Bevan; Fiscal Year: 2010
    ..abstract_text> ..
  57. GENETICS OF SALT SENSITIVITY IN AFRICAN AMERICANS
    Jackson Wright; Fiscal Year: 2004
    ..To this end, careful analytic attention will be paid to the development of improved phenotype definition, as well as to the consideration of gene-gene and gene-environment interaction. ..